A Pharmacokinetic Study Of SB-681323 In Subjects With Coronary Heart Disease Undergoing Percutaneous Intervention
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Study of SB-681323 (a novel p38 MAPkinase inhibitor) in subjects with documented coronary
heart disease (CHD) undergoing elective percutaneous coronary intervention (PCI).